CFB
ALLO icon

Cullen/Frost Bankers’s Allogene Therapeutics ALLO Stock Holding History

Cullen/Frost Bankers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351 Sell
144
-414
-74% -$830 ﹤0.01% 1338
2025
Q4 		$765 Sell
558
-4,395
-89% -$5.8K ﹤0.01% 1324
2025
Q3 		$6.14K Buy
4,953
+2
+0% +$2 ﹤0.01% 1142
2025
Q2 		$5.59K Buy
4,951
+2,986
+152% +$3.97K ﹤0.01% 1088
2025
Q1 		$2.87K Buy
1,965
+237
+14% +$447 ﹤0.01% 1119
2024
Q4 		$3.68K Buy
1,728
+177
+11% +$437 ﹤0.01% 1055
2024
Q3 		$4.34K Buy
1,551
+236
+18% +$629 ﹤0.01% 1023
2024
Q2 		$3.06K Buy
+1,315
New +$3.88K ﹤0.01% 1032

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cullen/Frost Bankers's ALLO Position: Q1 2026 in Review

Cullen/Frost Bankers reduced its Allogene Therapeutics (ALLO) stake by 74% in Q1 2026, selling an estimated $830 and leaving 144 shares worth $351. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Cullen/Frost Bankers first reported a position in ALLO in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.14K in Q3 2025. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Cullen/Frost Bankers held 144 shares of Allogene Therapeutics worth $351 as of Q1 2026.
  • Cullen/Frost Bankers sold 414 Allogene Therapeutics shares in Q1 2026, an estimated $830.
  • Allogene Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q1 2026, its #1338 holding.
  • Cullen/Frost Bankers first reported a position in Allogene Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Cullen/Frost Bankers's Allogene Therapeutics position peaked at $6.14K in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.